📊 FOXOW Key Takeaways
Is FOXOW a Good Investment? Thesis Analysis
FOXO Technologies demonstrates severe operational distress with massive negative profitability across all metrics, burning cash at an unsustainable rate while generating minimal revenue relative to its cost structure. The company faces critical liquidity constraints with a current ratio of 0.15x and declining financial health, making it unsuitable for fundamental-based investment.
Why Buy FOXOW? Key Strengths
- Positive revenue of $11.9M provides some operational activity base
- Moderate debt-to-equity ratio of 0.14x limits leverage risk relative to equity
- Substantial asset base of $52.1M suggests prior capitalization
FOXOW Investment Risks to Consider
- Severely negative net margin of -25.3% indicates operational model is fundamentally unprofitable
- Operating cash flow of -$3.8M with free cash flow of -$3.9M demonstrates unsustainable cash burn with only $628.6K in cash reserves
- Critical liquidity crisis with current ratio of 0.15x—company cannot cover short-term obligations with liquid assets
- Gross margin of only 0.1% on $11.9M revenue suggests either severe underpricing or inefficient cost structure
- Negative ROE of -14.9% and ROA of -5.8% indicate value destruction across all capital deployment
- Net loss of -$3.0M represents 25% of annual revenue, unsustainable trajectory
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway to insolvency
- Gross margin improvement and cost structure rationalization efforts
- Revenue growth relative to operating expense reduction
FOXOW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
FOXOW Profitability Ratios
FOXOW vs Healthcare Sector
How FOXO TECHNOLOGIES INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FOXOW Overvalued or Undervalued?
Based on fundamental analysis, FOXO TECHNOLOGIES INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FOXOW Balance Sheet & Liquidity
FOXOW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: FOXO TECHNOLOGIES INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
FOXOW Growth Metrics (YoY)
FOXOW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$1.9M | N/A |
| Q2 2025 | $27.5K | -$522.0K | N/A |
| Q1 2025 | $7.2K | -$616.5K | N/A |
| Q3 2024 | $10.0K | -$1.9M | N/A |
| Q2 2024 | $12.0K | -$2.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FOXOW Capital Allocation
FOXOW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for FOXO TECHNOLOGIES INC. (CIK: 0001812360)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FOXOW
What is the AI rating for FOXOW?
FOXO TECHNOLOGIES INC. (FOXOW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FOXOW's key strengths?
Claude: Positive revenue of $11.9M provides some operational activity base. Moderate debt-to-equity ratio of 0.14x limits leverage risk relative to equity.
What are the risks of investing in FOXOW?
Claude: Severely negative net margin of -25.3% indicates operational model is fundamentally unprofitable. Operating cash flow of -$3.8M with free cash flow of -$3.9M demonstrates unsustainable cash burn with only $628.6K in cash reserves.
What is FOXOW's revenue and growth?
FOXO TECHNOLOGIES INC. reported revenue of $11.9M.
Does FOXOW pay dividends?
FOXO TECHNOLOGIES INC. does not currently pay dividends.
Where can I find FOXOW SEC filings?
Official SEC filings for FOXO TECHNOLOGIES INC. (CIK: 0001812360) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FOXOW's EPS?
FOXO TECHNOLOGIES INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FOXOW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, FOXO TECHNOLOGIES INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FOXOW stock overvalued or undervalued?
Valuation metrics for FOXOW: ROE of -14.9% (sector avg: 15%), net margin of -25.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FOXOW stock in 2026?
Our dual AI analysis gives FOXO TECHNOLOGIES INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FOXOW's free cash flow?
FOXO TECHNOLOGIES INC.'s operating cash flow is $-3.8M, with capital expenditures of $110.0K. FCF margin is -32.4%.
How does FOXOW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -25.3% (avg: 12%), ROE -14.9% (avg: 15%), current ratio 0.15 (avg: 2).